Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine

Cancer Genetics and Cytogenetics

Volumn 196, Issue 1, 2010, Pages 96-104

  Prochazka, Pavel ^a   Hrabeta, Jan ^a   Vícha, Ales ^a   Eckschlager, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; HYDROXYUREA; MYC PROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRUCTURE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOSTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; GENES, MYC; HUMANS; HYDROXYUREA; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; VINCRISTINE;

EID: 70949105636     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.08.005     Document Type: Article

References (26)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3 (2003) 203-216
2. Schwab M. MYCN amplification in neuroblastoma. In: Brodeur G.M., Sawada T., Tsuchida Y., and Voute P.A. (Eds). Neuroblastoma (2001), Elsevier, Amsterdam
3. Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol 9 (1999) 319-325
4. Shimizu N., Nakamura H., Kadota T., Kitajima K., Oda T., Hirano T., and Utiyama H. Loss of amplified c-myc genes in the spontaneously differentiated HL-60 cells. Cancer Res 54 (1994) 3561-3567
5. Eckhardt S.G., Dai A., Davidson K.K., Forseth B.J., Wahl G.M., and Von Hoff D.D. Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci USA 91 (1994) 6674-6678
6. Canute G.W., Longo S.L., Longo J.A., Winfield J.A., Nevaldine B.H., and Hahn P.J. Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme. Neurosurgery 39 (1996) 976-983
7. Shimizu N., Misaka N., and Utani K. Nonselective DNA damage induced by a replication inhibitor results in the selective elimination of extrachromosomal double minutes from human cancer cells. Genes Chromosomes Cancer 46 (2007) 865-874
8. Freeman-Edward J., O'Neill S., Lastowska M., and Bown N. Expulsion of amplified MYCN from neuroblastoma tumor cells. Cancer Genet Cytogenet 116 (2000) 87-88
9. Valent A., Benard J., Clausse B., Barrois M., Valteau-Couanet D., Terrier-Lacombe M.J., Spengler B., and Bernheim A. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Am J Pathol 158 (2001) 1579-1584
10. Ambros I.M., Rumpler S., Luegmayr A., Hattinger C.M., Strehl S., Kovar H., Gadner H., and Ambros P.F. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation-sign of tumour cell revertance?. Eur J Cancer 33 (1997) 2043-2049
11. Von Hoff D.D., McGill J.R., Forseth B.J., Davidson K.K., Bradley T.P., Van Devanter D.R., and Wahl G.M. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci USA 89 (1992) 8165-8169
12. Narath R., Ambros I.M., Kowalska A., Bozsaky E., Boukamp P., and Ambros P.F. Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. Genes Chromosomes Cancer 46 (2007) 130-142
13. Kuroda H., Sugimoto T., Ueda K., Tsuchida S., Horii Y., Inazawa J., Sato K., and Sawada T. Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy. Int J Cancer 47 (1991) 732-737
14. Bedrnicek J., Vicha A., Jarosova M., Holzerova M., Cinatl Jr. J., Michaelis M., Cinatl J., and Eckschlager T. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma 52 (2005) 415-419
15. Kotchetkov R., Driever P.H., Cinatl J., Michaelis M., Karaskova J., Blaheta R., Squire J.A., Von Deimling A., Moog J., and Cinatl Jr. J. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol 27 (2005) 1029-1037
16. Pang E., Hu Y., Chan K.Y., Lai P.B., Squire J.A., Macgregor P.F., Beheshti B., Albert M., Leung T.W., and Wong N. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Lab Invest 85 (2005) 664-674
17. Kotchetkov R., Cinatl J., Blaheta R., Vogel J.U., Karaskova J., and Squire J. Hernaiz Driever P, Klingebiel T, Cinatl J, Jr. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104 (2003) 36-43
18. Azad M.B., Chen Y., Henson E.S., Cizeau J., McMillan-Ward E., Israels S.J., and Gibson S.B. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 4 (2008) 195-204
19. Shapiro D.N., Valentine M.B., Rowe S.T., Sinclair A.E., Sublett J.E., Roberts W.M., and Look A.T. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 142 (1993) 1339-1346
20. Villa O., Salido M., Perez-Vila M.E., Ferrer A., Arenillas L., Pedro C., Espinet B., Corzo C., Serrano S., Woessner S., Florensa L., and Solé F. Blast cells with nuclear extrusions in the form of micronuclei are associated with MYC amplification in acute myeloid leukemia. Cancer Genet Cytogenet 185 (2008) 32-36
21. De Preter K., Pattyn F., Berx G., Strumane K., Menten B., Van Roy F., De Paepe A., Speleman F., and Vandesompele J. Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons. BMC Genomics 5 (2004) 11
22. Prochazka P. Changes in amplification and expression of the MYCN gene in drug-resistant neuroblastoma cell lines. Cellular Oncol 30 (2008) 184-185
23. Yasuno T., Matsumura T., Shikata T., Inazawa J., Sakabe T., Tsuchida S., Takahata T., Miyairi S., Naganuma A., and Sawada T. Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line. Anticancer Res 19 (1999) 4049-4057
24. Mizushima Y., Kashii T., and Kobayashi M. Effect of cisplatin exposure on the degree of N-myc amplification in small cell lung carcinoma cell lines with N-myc amplification. Oncology 53 (1996) 417-421
25. Baumann Kubetzko F.B., Di Paolo C., Maag C., Meier R., Schafer B.W., Betts D.R., Stahel R.A., and Himmelmann A. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 25 (2004) 1839-1846
26. Bian X., Giordano T.D., Lin H.J., Solomon G., Castle V.P., and Opipari Jr. A.W. Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation. J Biol Chem 279 (2004) 4663-4669